Visana Health, a virtual women’s health clinic, has raised $24 million in a Series A funding round.
The round was led by Noro-Moseley Partners, with participation from Cigna Group Ventures, Intermountain Ventures, and existing backers Flare Capital Partners and Frist Cressey Ventures. The funds will support the expansion of Visana’s clinical services and the enhancement of its technology infrastructure.
“Women can come to us for any health concern they have,” said Joe Connolly, co-founder and CEO of Visana, in an interview with Fierce Healthcare. “Many arrive with symptoms rather than a diagnosis—and often, they’re dealing with more than one issue.”
Visana positions itself as a comprehensive medical home for women, addressing a full range of needs from menstruation through midlife, including complex, high-cost conditions like menopause, endometriosis, and PCOS. Currently, the company’s payer partnerships cover more than 35 million lives, with self-funded employer plans adding another 1 million. Visana expects to serve nearly 50,000 women this year.
“The women’s health market is at a tipping point,” Connolly said, noting especially strong demand from employers. He pointed to a Cigna study showing that 86% of employers are highly interested in a comprehensive women’s health solution.
Visana focuses on women ages 18 to 65 with complex health needs, taking a comprehensive, integrated approach to care. On average, Visana patients manage three to four chronic conditions, which the company addresses simultaneously to uncover root causes and reduce healthcare costs for payers.
“In the traditional system, care is fragmented across multiple providers and settings, with no one coordinating it all,” said CEO Joe Connolly. “That often leads to issues like polypharmacy, where no one’s connecting the dots.”
Women over 45, in particular, tend to incur healthcare costs 50% higher per member per month compared to the average, including men—a result of the significant health transitions and risks associated with menopause. Connolly sees value-based care (VBC) as a key solution.
Many of Visana’s payer contracts now include VBC elements such as care coordination fees or shared savings models. Employer interest in these arrangements is growing rapidly, Connolly noted, “as healthcare costs continue to rise at an unsustainable pace.” Visana reports that its approach has reduced employer medical costs by 34%, decreased unnecessary procedures by 78%, and generated over $2,400 in annual savings per member.
Between appointments, Visana keeps patients engaged with educational resources and allows them to communicate with their care team via text or messages. Through the Visana app, patients can log symptoms, which are actively monitored by clinicians.
Care begins with a 45-minute visit where providers screen for primary care, cardiometabolic, and behavioral health conditions. Based on this, they develop a personalized care plan. Follow-up frequency varies—some patients require ongoing visits, while others need less frequent check-ins.
For services that require in-person care—like labs, imaging, mammograms, cervical cancer screenings, or surgeries—Visana coordinates referrals. The clinic can manage mild to moderate anxiety and depression internally but refers out for more severe behavioral health needs or for prescriptions involving controlled substances.
Recently, Visana added an endocrinologist to its team to address a key access issue for patients facing long wait times—often between 6 to 12 months—for specialist care. A 2024 study reported an average 72-day wait to see an endocrinologist in the U.S.
Many Visana patients struggle with diabetes, thyroid issues, and weight management. Rather than defaulting to GLP-1 medications, Visana focuses on addressing the underlying causes. Connolly noted that 60% to 80% of GLP-1 spending in the commercial market is for women. “Employers and health plans appreciate our more targeted approach to obesity, helping patients meet weight loss goals without overreliance on medication,” he said.
Visana’s care approach may include GLP-1 medications when appropriate, but typically starts with alternatives like resistance training to prevent muscle loss and low-carb diets. In some cases, metformin is also prescribed for eligible patients.
A portion of the Series A funding will go toward expanding Visana’s AI capabilities. Currently, the company uses an internal AI tool to help providers quickly access clinical protocols, along with an external AI scribe that has been well-received by clinicians, according to CEO Joe Connolly.
At this time, Visana does not offer virtual abortion services. “Regulatory uncertainty makes it challenging to launch and sustain offerings when the legal landscape is constantly shifting,” Connolly said.
